Sunday, April 7, 2013


Sorin won an Investigational Device Exemption (IDE) from the FDA and a go-ahead to begin a trial of the SonR cardiac resynchronization therapy technology inside the PARADYM RF SonR CRT-D implant. The device uses a special SonRtip atrial pacing lead with a built-in hemodynamic sensor to monitor the heart. The defibrillator is then adjusted at the clinic on a weekly basis to perfect the timing of the electric signals.

No comments: